Events7th International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session S3. General of the event 7th International Electronic Conference on Medicinal Chemistry
Published date
03 Nov, 2021
Academic Editor
author-avatarJean Jacques Vanden Eynde
Citation
José Ignacio Klett-Mingo, Julio Cambronero-Plaza, Celia Pinto-Díez, Miriam Barragán-Usero, María V. T. Lobo, Víctor M. González, M. Elena Martín, Selection and characterization of aptamers to inhibit in vitro activity of histone acetyl transferase 1 (HAT1), in Proceedings of 7th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2021, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2021-11473
Share
Email
Facebook
Twitter
LinkedIn

Selection and characterization of aptamers to inhibit in vitro activity of histone acetyl transferase 1 (HAT1)

Julio Cambronero-Plaza 2
Miriam Barragán-Usero 1
image
1. Fundación para la Investigación Biomédica del Hospital Ramón y Cajal
2. Clicars
3. Aptus Biotech
4. Universidad de Alcalá d Henares
Abstract

Aptamers are single-stranded RNA or DNA oligonucleotides that are three-dimensionally structured and bind to a target molecule with high specificity and affinity selected from oligonucleotide libraries by systematic evolution of ligands by exponential enrichment (SELEX). This makes them stand as exceptional candidates for use as diagnostic tools or as antagonists or agonists of therapeutic targets, among others. Histone Acetyltransferase 1 (HAT1) belongs to the HATs family of enzymes. In fact, it was the first to be described within this group, although it is the least known. However, in recent years it has aroused growing interest due to its involvement in multiple pathologies. The Overexpression of this enzyme is related to a poor prognosis and survival in cancer patients as well as viral infections and other pathologies in which inflammation occurs. Thus, many authors propose HAT1 as a potential therapeutic target. In this work, aptamers were developed against this target in order to inhibit its activity. After 6 rounds of selection, 2 specific aptamers against HAT1 were obtained and were subsequently characterized and optimized. Finally, an in vitro HAT1 activity assay was performed, showing that both aptamers and their modified sequences were able to inhibit the activity of this enzyme at concentrations in the nanomolar range.

Keywords
Aptamer
SELEX
HAT1
therapeutic target
inhibition
Poster
Poster ECMC 2021 J. Ignacio Klett Mingo .pdf
Exploring effects of temperature on the catalytic site of non-structural protease 2 (nsP2) from Chikungunya virus by using molecular dynamics simulations and DFT calculations
Fumiquinazoline related alkaloids: Synthesis and evaluation of their antibacterial activities